¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oncogene theory"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • clonal selection theory
    Ŭ·Ð¼±Åü³
  • convergence-projection theory
    ÆøÁÖÅõ»ç¼³, ´«¸ðÀ½Åõ»ç¼³
  • corpuscular theory
    ÀÔÀÚ¼³
  • developmental theory
    ¹ß´ÞÀÌ·Ð
  • five element theory
    ¿À¿ø¼ÒÀÌ·Ð
  • family system theory
    °¡Á·Ã¼°è·Ð
  • gate-control theory
    ¹®Á¶ÀýÀÌ·Ð
  • general system theory
    ÀϹÝü°è·Ð
  • instinct theory
    º»´ÉÀÌ·Ð
  • instructive theory
    (Ç×ü»ý»ê)Áö½Ã¼³
  • object relation theory
    ´ë»ó°ü°è·Ð
  • psychoanalytic theory
    Á¤½ÅºÐ¼®ÀÌ·Ð
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • theory
    Çм³, ¼³, ÀÌ·Ð
  • multiple causation theory
    Áúº´¹ß»ý´Ù¿äÀμ³
  • psychoanalytic theory
    Á¤½ÅºÐ¼®ÀÌ·Ð
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ, Á¾¾ç¿ø
  • signaling oncogene
    ½ÅÈ£Á¾¾çÀ¯ÀüÀÚ
  • alternation theory
    ±³¹ø¼³
  • backward failure theory
    ÈĹæÀå¾Ö¼³
  • centrifugal sprouting theory
    ¿ø½É½ÏÆ·¿ò¼³, ¿ø½É¹ß¾Æ¼³
  • clonal selection theory
    Ŭ·Ð¼±Åü³
  • conditioning theory
    Á¶°ÇÈ­ÀÌ·Ð
  • convergence-projection theory
    ÆøÁÖÅõ»ç¼³
  • corpuscular theory
    ÀÔÀÚ¼³
  • countercurrent theory
    ¿ª·ù¼³, ´ëÇâ·ù¼³
  • cross-linking theory
    ±³Â÷¿¬°üÀÌ·Ð
  • developmental theory
    ¹ß´ÞÀÌ·Ð
  • dichotomous theory
    À̺йýÇм³
  • dipole theory
    ½Ö±Ø¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Erb-A oncogene
    Erb-A ¾ÏÀ¯ÀüÀÚ
  • Erb-B oncogene
    Erb-B ¾ÏÀ¯ÀüÀÚ
  • Fins oncogene
    Fins ¾ÏÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • Frequency theory of hearing
    û°¢(ôéÊÆ)ÀÇ Áøµ¿¼ö(òÉÔÑâ¦) Çм³(ùÊàã)
  • Young-Helmholtz theory
    ¿µ-Ç︧ȦÃ÷ ¼³
  • adsorption theory
    ÈíÂø¼³, Èí¼ö¼³.
  • aging,free radical theory
    À¯¸®±â ¼³(ë´×îÐñàã)
  • alternation theory
    ±³¹ø¼³(ÎßÛãæò).
  • gate control theory
    (°ü)¹®Á¶Àý¼³(μڦðàï½àã).
  • general system theory
    ÀϹÝü°è(ÀÌ)·Ð(ìéÚõô÷ͧìµÖå)
  • germ line theory
    ³»¸²¹°·Á¹Þ±â¼³ (Ç×ü´Ù¾ç¼ºÀÇ)
  • glucostat theory
    Ç×´ç±â¼³(ù÷ÓØÐñæò).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷¾ÏÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ
  • oncogene
    Á¾¾çÀ¯ÀüÀÚ(ðþåËë¶îîí­), Á¾¾ç¿ø(ðþåË¿ø)
  • proto-oncogene
    ¿øÇü¾ÏÀ¯ÀüÀÚ, ¿øÇü¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿øÁ¾¾çÀ¯ÀüÀÚ
  • proto-oncogene
    ¿ø¹ß¾ÏÀ¯ÀüÀÚ(ê«Û¡äßëºîîí­)
  • trk proto-oncogene
    trk¿øÇüÁ¾¾çÀ¯ÀüÀÚ
  • adsorption theory
    ÈíÂø¼³, Èí¼ö¼³.
  • aging,free radical theory
    À¯¸®±â ¼³(ë´×îÐñàã)
  • alternation theory
    ±³¹ø¼³(ÎßÛãæò).
  • atomic theory
    ¿øÀÚ¼³(¡­æò).
  • autonomic theory
    ÀÚÀ²¼º ÀÌ·Ð
  • backward failure (theory)
    ÈĹæÀå¾Ö(¼³) (¡­î¡äôæò).
  • backward failure (theory)
    ÈĹæÀå¾Ö(¼³) (ý­Û°î¡äô(àâ))
  • chemiosmotic theory
    È­ÇлïÅõ¾Ð·Ð
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene theory
    ¾ÏÀ¯ÀüÀÚÀÌ·Ð(äßë¶îîí­ìµÖå)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cellular oncogene
    ¼¼Æ÷ ¾ÏÀ¯ÀüÀÚ(á¬øàäßë¶îîí­)
  • oncogene
    ¾ÏÀ¯ÀüÀÚ(äßë¶îîí­)
  • accumulation theory
    ´©Àû·Ð (ÒéîÝÖå)
  • active aldehyde theory
    Ȱ¼º(üÀàõ)¾Ëµ¥ÇÏÀ̵å·Ð(Öå)
  • Bronsted-Lowry theory
    ºê·Ð½ºÅ×µå Ã˸ŷÐ(õºØÚÖå)
  • Burnet's theory
    ¹ö³Ý ·Ð(Öå)
  • Busch theory
    ºÎ½¬ ·Ð(Öå)
  • cholesterol intoxication theory
    ÄÝ·¹½ºÅ×·Ñ Áßµ¶ÀÌ·Ð(ñéÔ¸ìµÖå)
  • clonal selection theory
    Ŭ·Ð ¼±Åà ÀÌ·Ð(àÔ÷ÉìµÖå)
  • collision theory
    Ãæµ¹ÀÌ·Ð(õúÔÍ×âÖå)
  • convergence theory of cancer
    "¾Ï ¼ö·Å·Ð(äßâ¥Ö°Öå),(ÔÒ) Greenstein hypothesis"
  • crystal field theory
    °áÁ¤ Àå·Ð(Ì¿ïÜíÞÖå)
  • Ehrlich's receptor theory
    ¿¡¸¦¸®È÷ ¼ö¿ëüÀÌ·Ð(áôé»ô÷×âÖå)
  • elective theory
    ¼±Å÷Ð(àÔ÷ÉÖå)
  • error theory
    ¿À·ù ÀÌ·Ð (è¦×½×âÖå)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • theory
    ¼³, ÀÌ·Ð
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
SDT sensory detection theory; right sacrotransverse [fetal position] [Lat. sacrodextra transversa]; sign...
DOI date of injury; died of injuries; diffusion of innovations [theory]
MAUT multi-attribute utility theory
theor theory, theoretical
TSD target-skin distance; Tay-Sachs disease; theory of signal detectability
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
c-onc cellular oncogene
GRO-alpha Growth Regulated Oncogene-alpha
GROalpha Growth-related oncogene-alpha
DFT Density Functional Theory
IRT Item Response Theory
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cellular oncogene
    ¼¼Æ÷ ¾Ï À¯ÀüÀÚ
    ¼¼Æ÷ÀÇ ¿øÀο¡ ÀÇÇØ¼­ Á¾¾çÇü¼ºÀ» ÀÏÀ¸Å°´Â À¯ÀüÀÚ.
  • acid decalcification theory
    Żȸ¼³
    ¿ì½ÄÀÇ º´Àο¡ °üÇÑ ¼³·Î ¼¼±ÕÀ» »ý»êÇÏ´Â »ê ȤÀº ´çºÐÀ» Æ÷ÇÔÇÑ À½½Ä¹°ÀÇ Àܻ翡 ¹ßÈ¿¿¡ ÀÇÇÏ¿© »ý±ä »êÀÌ Ä¡ÁúÀ» ŻȸÇÏ¿© ¿ì½ÄÀÌ »ý±ä´Ù´Â ¼³.
  • acidogenic theory
    »êÀηÐ, »ê»ý¼º ÀÌ·Ð, È­ÇÐ ¼¼±Õ¼³
    Ä¡¾Æ ¿ì½ÄÀº chemico-
  • aging,free radical theory
    À¯¸®±â¼³
  • alternation theory
    ±³¹ø¼³
  • apposition theory
    ºÎÂø¼³
  • biophysical theory
    »ý¹°¸®Çм³
  • Burnet's clonal selection theory
    ?
  • chemo-parasitic theory
    È­ÇÐ ¼¼±Õ¼³
    ¿ì½ÄÀÇ ¿øÀο¡ °üÇÏ¿© Miller°¡ ¼¼¿î Çм³. ¿ì½ÄÀÇ ¹ß»ýÀº Ä¡¾ÆÀÇ ÁÖü¸¦ ÀÌ·é ¼®È¸¿°ÀÇ Å»È¸À̰í, ±× ¿øÀÎÀÌ µÇ´Â »êÀº À½½Ä¹° Áß¿¡ Æ÷ÇԵǾî Àִ ź¼öÈ­¹°À» ±¸°­³»ÀÇ ¼¼±ÕÀÌ ¹ßÈ¿ÇϹǷΠÀÎÇØ¼­ »ý±â´Â À¯±â»êÀ̶ó´Â °¡¼³À» ¼¼¿ü´Ù. Miller´Â ¿ì½Ä Á¶Á÷À» È­ÇÐÀûÀ¸·Î ºÐ¼®ÇÏ°í ±×°Í¿¡ Æ÷ÇԵǾî ÀÖ´Â Ä®½·°ú À¯±âÁúÀÇ ¾çÀÌ ÀÌ»óÇÏ°Ô °¨¼ÒµÇ¾î ÀÖ´Â °ÍÀ» ¾Ë¾Ò´Ù. Áï ¿ì½Ä Ç¥ÃþºÎÀÇ ¿¬È­ »ó¾ÆÁúÀº Á¤»óÀÇ Ä¡Áú¿¡ ºñÇÏ¿© 92.5%ÀÇ Ä®½·°ú 39.4%ÀÇ À¯±âÁúÀÌ ¼Õ½ÇµÇ¾î ÀÖ°í ¿ì½Ä ½ÉºÎ¿¡¼­´Â 22.0%ÀÇ Ä®½· »ó½ÇÀ» ³ªÅ¸³Â´Ù. ±×·¯¹Ç·Î ±×´Â ½ÇÇèÀ» ÅëÇÏ¿© Ä¡¾Æ¿¡ À¯±â»ê°ú »§°¡·ç¸¦ ¼¯Àº °ÍÀ» ¾È¿¡ ºÙ¿© ³õÀº °á°ú, »ýÈ­ÇÐÀûÀ¸·Î ¿ì½Ä°ú ºñ½ÁÇÑ »óŰ¡ ÀϾ´Â °ÍÀ» ±ú´Ý°í, ¿ì½ÄÀÇ °æ¿ì´Â »êÀÌ Å« ÀÛ¿ëÀ» Çϸç, ±× À¯±â»êÀº »ó¾Æ¼¼°ü³»³ª Ä¡¾ÆÀÇ Ç¥¸é¿¡¼­ º¼ ¼ö ÀÖ´Â ´ÙÁ¾ ´Ù¾çÀÇ ¼¼±Õ¿¡ ÀÇÇØ¼­ À½½Ä¹° Àܻ翡 Æ÷ÇÔµÈ Åº¼öÈ­¹°ÀÇ ¹ßÈ¿¿¡ ÀÇÇÑ °ÍÀ̶ó°í »ý°¢ÇÏ¿´À¸³ª ±×´Â ±× ÁÖ¿ªÀ» ¸ÃÀº ¼¼±ÕÀÌ ¹«¾ùÀΰ¡´Â ¾ð¸íÇÏÁö ¾Ê¾Ò´Ù. ÀÌ È­ÇÐ ¼¼±Õ¼³Àº Èļ¼±îÁö °­ÇÑ ¿µÇâÀ» ¹ÌÄ¡°í ¿ì½ÄÀÇ ¼¼±ÕÇÐÀû ¿¬±¸ÀÇ ÁÖ·ù¸¦ ÀÌ·ç¾î ¿Ô´Ù.
  • clonal selection theory
    Ŭ·Ð ¼±Åü³
  • Combinational theory
    Á¶ÇÕ¼³
    Ç×ü ¹ßÇöÀÇ ´Ù¾ç¼ºÀ» ¼ø¿­ Á¶ÇÕ¿¡¼­ ±¸ÇÏ´Â Çм³.
  • contagium theory
    Àü¿°¼³, °¨¿°¼³
  • doublet theory
    ÀÌÁß±Ø ¼³
  • Ehrlich`s side chain theory
    ¿¡¸¦¸®È÷ÀÇ Ãø¼â¼³
    Ç×ü »ý»ê ±âÀü¿¡ ´ëÇÏ¿© Á¦¾ÈµÈ °¡¼³ÀÇ Çϳª. ¸ðµç ü ¼¼Æ÷ Ç¥¸é¿¡´Â Ãø¼â¶ó°í ÇÏ´Â ¼ö¿ëü°¡ ÀÖ°í, À̰Ϳ¡ ´ëÀÀÇÏ´Â Ç׿øÀÌ °áÇÕÇϸé Ȱ¼ºÈ­ µÇ°í, Ãø¼â°¡ °úÀ× »ý»êµÇ¾î Ç×ü·Î¼­ Ç÷·ù ¼Ó¿¡ ¹æÃâµÈ´Ù°í ÇÏ´Â »ý°¢. Ç×ü »ý»êÀÇ ¼±Åü³ÀÇ ÃÖÃÊÀÇ °ÍÀÌ´Ù.
  • epoigenetic theory
    Èļº¼³
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
recessive oncogene <molecular biology> A single copy of this gene issufficient to suppress cell proliferation, the loss of both copies of the gene contributes to cancer formation.
(09 Oct 1997)
viral oncogene <molecular biology> A viral gene that contributes to cancer development in vertebrate hosts.
(09 Oct 1997)
cellular oncogene <molecular biology> A normal gene that, when mutated or improperly expressed, can cause cancer to develop.
(09 Oct 1997)
c-oncogene <molecular biology> A normal gene which has a tumour-producing insert that may have originated from a virus in it, turning it into a proto-oncogene.
When these genes are sufficiently mutated, amplified, or over-expressed (transcribed too many times), they can begin to produce cancers.
(05 Jan 1998)
proto-oncogene <molecular biology> The normal, cellular equivalent of an oncogene, thus usually a gene involved in the signalling or regulation of cell growth. In general, cellular proto-oncogenes are prefixed with a c, rather than their abnormal viral counterparts, that are prefixed with a v, for example c myc and v myc.
They are fragments of DNA, related to oncogenes but are the normal switches used to control growth and tissue repair.
(06 Oct 1997)
proto-oncogene protein p21(ras) Cellular protein encoded by the c-ras genes. The protein has GTPase activity and is involved in transmembrane signal transduction as a guanine nucleotide binding protein. Elevated levels of p21 c-ras have been associated with neoplasia.
(12 Dec 1998)
proto-oncogene protein pp60(c-src) <enzyme> Membrane-associated tyrosine-specific kinase encoded by the c-src genes. It has an important role in cellular growth control. Truncation of carboxy-terminal residues in pp60(c-src) leads to pp60(v-src) which has the ability to transform cells. This kinase pp60 c-src should not be confused with csk, also known as c-src kinase.
Registry number: EC 2.7.1.-
(12 Dec 1998)
proto-oncogene proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
(12 Dec 1998)
proto-oncogene proteins c-abl Membrane proteins encoded by the c-abl genes. They exhibit tyrosine kinase activity and play a role in normal haematopoiesis especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific n-terminal amino acids are deleted, releasing the kinase from negative regulation.
(12 Dec 1998)
proto-oncogene proteins c-bcl-2 Membrane proteins encoded by the bcl-2 genes and serving as a potent inhibitor of cell death by apoptosis. The proteins are found on mitochondrial, microsomal, and nuclear membrane sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
(12 Dec 1998)
proto-oncogene proteins c-erbb-2 Cellular proteins in the epidermal growth factor receptor family encoded by the c-erbb genes. These proteins are overexpressed in a significant portion of adenocarcinomas found at various sites, especially in the breast. Gene amplification appears to be the predominant method leading to overexpression.
(12 Dec 1998)
proto-oncogene proteins c-fos Cellular DNA-binding proteins encoded by the c-fos genes (genes, fos). They are involved in growth-related transcriptional control. C-fos combines with c-jun (proto-oncogene proteins c-jun) to form a c-fos/c-jun heterodimer (transcription factor ap-1) that binds to the tre (tpa-responsive element) in promoters of certain genes.
(12 Dec 1998)
proto-oncogene proteins c-jun Cellular DNA-binding proteins encoded by the c-jun genes (genes, jun). They are involved in growth-related transcriptional control. There appear to be three distinct functions: dimerization (with c-fos), DNA-binding, and transcriptional activation. Oncogenic transformation can take place by constitutive expression of c-jun.
(12 Dec 1998)
proto-oncogene proteins c-kit Tyrosine kinase membrane receptors which are the natural ligands for mast cell growth factor (steel factor). This interaction is crucial for the development of haematopoietic, gonadal, and pigment stem cells.
(12 Dec 1998)
proto-oncogene proteins c-met <enzyme> A transmembrane tyrosine kinase that is the receptor for hepatocyte growth factor (scatter factor). It consists of an extracellular alpha chain which is disulfide linked to the transmembrane beta chain. The cytoplasmic portion contains the catalytic domain and critical sites for the regulation of kinase activity.
Registry number: EC 2.7.11.-
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • oncogene
    ¹ß¾ÏÀ¯ÀüÀÚ
  • theory
    ÀÌ·Ð,-¼³,Àǰß
  • Development theory
    (»ý)(¶ó¸¶¸£Å©ÀÇ)ÁøÈ­·Ð
  • Dow theory
    ´Ù¿ì ÀÌ·Ð(½ÃÀåÀÇ °¡°Ý º¯µ¿¿¡ ÀÔ°¢ÇÑ Áõ±Ç ½Ã¼¼ÀÇ ¿¹»ó¹ý)
  • Einstein theory
    ¾ÆÀν¶Å¸ÀÎÀÇ »ó´ë¼º ¿ø¸®
  • atomic theory
    ¿øÀÚ·Ð
  • atonic theory
    ¿øÀÚ·Ð
  • big bang theory
    ¿ìÁÖ°¡ Æø¹ß¿¡ ÀÇÇÏ¿© »ý¼ºÇÏ°í ÆØÃ¢;¼öÃàÀ» µÇÇ®ÀÌÇÑ´Ù´Â ¼³
  • communication(s) theory
    Á¤º¸ÀÌ·Ð
  • corpuscular theory
    ÀÔÀÚ¼³
  • desk theory
    ʻ󰸷Ð
  • diluvial theory
    (ÁöÁú)È«¼ö¼³(³ë¾ÆÀÇ È«¼ö¸¦ Áö±¸ ¿ª»ç»ó ÃÖ´ëÀÇ »ç½Ç·Î º¸¸ç È­¼®À» È«¼ö·Î »ç¸êÇÑ »ý¹°ÀÇ À¯Ã¼·Î º½)
  • domino theory
    µµ¹Ì³ë ÀÌ·Ð(ÇÑ ³ª¶ó°¡ °ø»êÈ­µÇ¸é ÀÎÁ¢ ±¹°¡µéµµ °ø»êÈ­µÈ´Ù´Â)
  • field theory
    Àå·Ð;ÀåÀÇ ÀÌ·Ð
  • frontier orbital theory
    ÇÁ·ÐƼ¾î ÀüÀÚ ±Ëµµ ÀÌ·Ð
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á